G-protein-coupled estrogen receptor-30 gene polymorphisms are associated with uterine leiomyoma risk

Bosnian Journal of Basic Medical Sciences

Volumn 16, Issue 1, 2016, Pages 39-45

  Kasap, Burcu ^a   Turhan, Nilgün Öztürk ^a   Edgünlü, Tuba ^a   Duran, Müzeyyen ^a   Akbaba, Eren ^a   Öner, Gökalp ^a  

^a MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

Author keywords

Estrogen receptor; Gene; GPR30 (GPER1); Polymorphism; Uterine leiomyoma

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; FOLLITROPIN; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN;

ADULT; ALLELE; CASE CONTROL STUDY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; LEIOMYOMA; METABOLISM; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; TURKEY; UTERUS CANCER;

ADULT; ALLELES; CASE-CONTROL STUDIES; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEIOMYOMA; MIDDLE AGED; MODELS, STATISTICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; TURKEY; UTERINE NEOPLASMS;

EID: 84959543712     PISSN: 15128601     EISSN: 18404812     Source Type: Journal    
DOI: 10.17305/bjbms.2016.683     Document Type: Article

References (39)

1. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100-107. http://dx.doi.org/10.1067/mob.2003.99.
2. Ekin M, Cengiz H, Öztürk E, Kaya C, Yasar L, Savan K. Genitourinary symptoms and their effects on quality of life in women with uterine myomas. Int Urogynecol J. 2014;25(6):807-810 http://dx.doi.org/10.1007/s00192-013-2295-4.
3. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: A review. Environ Health Perspect. 2003;111(8):1037‑1054. http://dx.doi.org/10.1289/ehp.5787.
4. Grandien K, Berkenstam A, Gustafsson JA. The estro­gen receptor gene: Promoter organization and expres­sion. Int J Biochem Cell Biol. 1997;29(12):1343-1369 http://dx.doi.org/10.1016/S1357-2725(97)89967-0.
5. Pedram A, Razandi M, Levin ER. Nature of functional estrogen recep­tors at the plasma membrane. Mol Endocrinol. 2006;20(9):1996-2009. http://dx.doi.org/10.1210/me.2005-0525.
6. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor medi­ates rapid cell signaling. Science. 2005;307(5715):1625-1630. http://dx.doi.org/10.1126/science.1106943.
7. Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, et al. G protein-coupled receptor 30 localizes to the endo­plasmic reticulum and is not activated by estradiol. Endocrinology. 2008;149(10):4846-4856. http://dx.doi.org/10.1210/en.2008-0269.
8. Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol. 2005;67:285‑308. http://dx.doi.org/10.1146/annurev.physiol.67.040403.115914.
9. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol. 2009;5(6):421-427. http://dx.doi.org/10.1038/nchembio.168.
10. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, et al. GPR30: A novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol. 2007;196(4):386.e1-9; discussion 386.e9-11.
11. Huang GS, Gunter MJ, Arend RC, Li M, Arias-Pulido H, Prossnitz ER, et al. Co-expression of GPR30 and ERbeta and their association with disease progression in uterine car­cinosarcoma. Am J Obstet Gynecol. 2010;203(3):242.e1-5. http://dx.doi.org/10.1016/j.ajog.2010.04.046.
12. Plante BJ, Lessey BA, Taylor RN, Wang W, Bagchi MK, Yuan L, et al. G protein-coupled estrogen receptor (GPER) expression in nor­mal and abnormal endometrium. Reprod Sci. 2012;19(7):684-693. http://dx.doi.org/10.1177/1933719111431000.
13. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, et al. Distribution of GPR30, a seven mem­brane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res. 2006;12(21):6359-6366. http://dx.doi.org/10.1158/1078-0432.CCR-06-0860.
14. He YY, Cai B, Yang YX, Liu XL, Wan XP. Estrogenic G pro­tein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-ac­tivated protein kinase pathway. Cancer Sci. 2009;100(6):1051-1061. http://dx.doi.org/10.1111/j.1349-7006.2009.01148.x.
15. Tica AA, Dun EC, Tica OS, Gao X, Arterburn JB, Brailoiu GC, et al. G protein-coupled estrogen receptor 1-mediated effects in the rat myometrium. Am J Physiol Cell Physiol. 2011;301(5):C1262-1269. http://dx.doi.org/10.1152/ajpcell.00501.2010.
16. Welsh T, Johnson M, Yi L, Tan H, Rahman R, Merlino A, et al. Estrogen receptor (ER) expression and function in the pregnant human myometrium: Estradiol via ERα activates ERK1/2 sig­naling in term myometrium. J Endocrinol. 2012;212(2):227-238. http://dx.doi.org/10.1530/JOE-11-0358.
17. Hermon TL, Moore AB, Yu L, Kissling GE, Castora FJ, Dixon D. Virchows Arch. Estrogen receptor alpha (ERalpha) phospho-ser­ine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. 2008;453(6):557-569.
18. Jakimiuk AJ, Bogusiewicz M, Tarkowski R, Dziduch P, Adamiak A, Wróbel A, et al. Estrogen receptor alpha and beta expression in uterine leiomyomas from pre­menopausal women. Fertil Steril. 2004;82:1244-1249. http://dx.doi.org/10.1016/j.fertnstert.2004.02.130.
19. Tian R, Wang Z, Shi Z, Li D, Wang Y, Zhu Y, et al. Differential expression of G-protein-coupled estrogen receptor-30 in human myometrial and uterine leiomyoma smooth muscle. Fertil Steril. 2013;99(1):256-263. http://dx.doi.org/10.1016/j.fertnstert.2012.09.011.
20. Giess M, Lattrich C, Springwald A, Goerse R, Ortmann O, Treeck O. GPR30 gene polymorphisms are associated with proges­terone receptor status and histopathological characteristics of breast cancer patients. J Steroid Biochem Mol Biol. 2010;118(1‑2):7‑12. http://dx.doi.org/10.1016/j.jsbmb.2009.09.001.
21. Andersen J. Growth factors and cytokines in uterine leio­myomas. Semin Reprod Endocrinol. 1996;14(3):269-282. http://dx.doi.org/10.1055/s-2007-1016336.
22. Olde B, Leeb-Lundberg LM. GPR30/GPER1: Searching for a role in estrogen physiology. Trends Endocrinol Metab. 2009;20(8):409‑416. http://dx.doi.org/10.1016/j.tem.2009.04.006.
23. Haas E, Meyer MR, Schurr U, Bhattacharya I, Minotti R, Nguyen HH, et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estro­gen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension. 2007;49(6):1358-1363. http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.089995.
24. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, et al. GPR30 predicts poor sur­vival for ovarian cancer. Oncol. 2009;114(3):465-471. http://dx.doi.org/10.1016/j.ygyno.2009.05.015.
25. Sirianni R, Chimento A, Ruggiero C, De Luca A, Lappano R, Andò S, et al. Endocrinology. The novel estrogen receptor, G pro­tein-coupled receptor 30, mediates the proliferative effects induced by 17beta-estradiol on mouse spermatogonial GC-1 cell line. 2008;149(10):5043-5051.
26. Kleuser B, Malek D, Gust R, Pertz HH, Potteck H. 17-Beta-estradiol inhibits transforming growth factor-beta sig­naling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30. Mol Pharmacol. 2008;74(6):1533-1543. http://dx.doi.org/10.1124/mol.108.046854.
27. Chevalier N, Paul-Bellon R, Camparo P, Michiels JF, Chevallier D, Fénichel P. Genetic variants of GPER/GPR30, a novel estrogen-related G protein receptor, are associated with human seminoma. Int J Mol Sci. 2014;15(1):1574-1589. http://dx.doi.org/10.3390/ijms15011574.
28. Korkmaz HA, Edgünlü T, Eren E, Demir K, Çakir ED, Çelik SK, et al. GPR30 Gene Polymorphisms Are Associated with Gynecomastia Risk in Adolescents. Horm Res Paediatr. 2015;83(3):177-182. http://dx.doi.org/10.1159/000369013.
29. Snieder H, MacGregor AJ, Spector TD. Genes control the cessation of a woman's reproductive life: A twin study of hysterectomy and age at menopause. J Clin Endocrinol Metab. 1998;83(6):1875-1880. http://dx.doi.org/10.1210/jc.83.6.1875.
30. Luoto R, Kaprio J, Rutanen EM, Taipale P, Perola M, Koskenvuo M. Heritability and risk factors of uterine fibroids--the Finnish Twin Cohort study. Maturitas. 2000;37(1):15-26. http://dx.doi.org/10.1016/S0378-5122(00)00160-2.
31. Cha PC, Takahashi A, Hosono N, Low SK, Kamatani N, Kubo M, et al. A genome-wide association study identifies three loci associated with susceptibility to uterine fibroids. Nat Genet. 2011;43(5):447-450. http://dx.doi.org/10.1038/ng.805.
32. Edwards TL, Hartmann KE, Velez Edwards DR. Variants in BET1L and TNRC6B associate with increasing fibroid volume and fibroid type among European Americans. Hum Genet. 2013;132(12):1361‑1369. http://dx.doi.org/10.1007/s00439-013-1340-1.
33. Aissani B, Zhang K, Wiener H. Follow-up to genome-wide linkage and admixture mapping studies implicates com­ponents of the extracellular matrix in susceptibility to and size of uterine fibroids. Fertil Steril. 2015;103(2):528-534.e13. http://dx.doi.org/10.1016/j.fertnstert.2014.10.025.
34. Morosova EB, Chukhlovin AB, Kulagina NV, Kipich NV, Totolian AA. Functional gene polymorphism of matrix metalloproteinase-1 is associated with benign hyperpla­sia of myo- and endometrium in the Russian popula­tion. Genet Test Mol Biomarkers. 2012;16(9):1032-1037. http://dx.doi.org/10.1089/gtmb.2011.0376.
35. Attar R, Atasoy H, İnal-Gültekin G, Timirci-Kahraman Ö, Güleç-Yilmaz S, Dalan AB, et al. The effects of PON1 gene Q192R variant on the development of uterine leiomyoma in Turkish patients. In Vivo. 2015;29(2):243-246.
36. Gultekin GI, Yilmaz SG, Kahraman OT, Atasoy H, Dalan AB, Attar R, et al. Lack of influence of the ACE1 gene I/D polymor­phism on the formation and growth of benign uterine leiomyoma in Turkish patients. Asian Pac J Cancer Prev. 2015;16(3):1123-1127. http://dx.doi.org/10.7314/APJCP.2015.16.3.1123.
37. Shen Y, Ren ML, Xu J, Xu Q, Ding YQ, Wu ZC, et al. A multicenter case-control study on screening of single nucleotide polymorphisms in estrogen-metabolizing enzymes and susceptibility to uterine leio­myoma in han chinese. Gynecol Obstet Invest. 2014;77(4):224-230. http://dx.doi.org/10.1159/000360083.
38. Ates O, Demirturk F, Toprak M, Sezer S. Polymorphism of cat­echol-o-methyltransferase and uterine leiomyoma. Mol Cell Biochem. 2013;375(1-2):179-183.
39. Alleyne AT, Austin S, Williams A. Distribution of CYP17α polymorphism and selected physiochemical factors of uter­ine leiomyoma in Barbados. Meta Gene. 2014; 9(2):358-365. http://dx.doi.org/10.1016/j.mgene.2014.03.006.